

CORRECTION

Open Access



Correction to: A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation

Shannon Robin^{1†}, Khalil Ben Hassine^{1†}, Jayaraman Muthukumar², Simona Jurkovic Mlakar¹, Maja Krajinovic³, Tiago Nava^{1,4†}, Chakradhara Rao S. Uppugunduri^{1*†} and Marc Ansari^{1,4†}

Correction to: *BMC Mol Cell Biol* 23, 5 (2022)

<https://doi.org/10.1186/s12860-021-00402-5>

Following publication of the original article [1], the following typesetting error was noticed:

- 1) The equal contribution note has been updated.
- 2) Table 1, column 4 (InterPro-Protein Family), row 3 “ransferase” should be “transferase”
- 3) The footnote for Table 3 was mistakenly added to the body text (last para in pg 10 [1], continued as para 1 in pg.12 i.e. “Results are presented as the mean±SD.....to compare our results with other putative ligands” The correct Table 3 and footnote are supplied below.
- 4) The footnote for Table 5 was mistakenly added to the body text. The correct Table 5 and footnote are supplied below.
- 5) In the section *Molecular dynamics simulations with GROMACS* “Eight compounds showing ΔG value of ≤ -1.0 kcal/mol predicted by AutoDock Vina”, should be “Eight compounds showing ΔG value of ≤ -0.1 kcal/mol predicted by AutoDock Vina”

The original article can be found online at <https://doi.org/10.1186/s12860-021-00402-5>.

*Correspondence: Chakradhara.Uppugunduri@unige.ch

[†]Shannon Robin and Khalil Ben Hassine contributed equally to this work and are considered co-first authors.

[†]Tiago Nava, Chakradhara Rao S. Uppugunduri and Marc Ansari contributed equally to this work and are considered co-last authors.

¹ CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland

Full list of author information is available at the end of the article

Author details

¹CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland. ²Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida 201306, India. ³Charles-Brunet Cancer Center, CHU Sainte-Justine Research Center, Departments of Pediatrics and Pharmacology, University of Montreal, Montreal, Quebec, Canada. ⁴Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland.

Published online: 27 January 2022



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 3 Estimated binding free energy and dissociation constant between putative substrates and human UGT2B10

Model	Substrate	Ligand	ΔG [Kcal/mol \pm SD]	Kd[mM]
UGT2B10 with UDPGlcA	Controls	Amitriptyline	-1.9 \pm 0.2	39.0
		Itraconazole	19.0 \pm 0.5	1.1 $\times 10^{17}$
	Putative ligands	4-hydroxy voriconazole	-1.0 \pm 0.0	184.7
		Acetaminophen	-5.5 \pm 0.0	0.1
		Cyclosporine A	154.9 \pm 2.9	1.8 $\times 10^{118}$
		Bilirubine	6.9 \pm 0.0	1.2 $\times 10^{15}$
		Dihydroxy voriconazole	-0.6 \pm 0.0	363.0
		Hydroxy voriconazole	-1.2 \pm 0.1	125.0
		Lorazepam	-2.6 \pm 0.0	12.4
		Methotrexate	-0.5 \pm 0.5	567.3
		Methylprednisolone	5.2 \pm 0.1	6.2 $\times 10^6$
		Mycophenolic acid	-5.1 \pm 0.1	0.2
		Posaconazole	17.6 \pm 0.3	8.8 $\times 10^{15}$
		UDCA-G1	2.2 \pm 0.1	4.4 $\times 10^4$
		UDCA-G2	1.2 \pm 0.1	8053.6
		Ursodeoxycholic acid	2.2 \pm 0.1	4.4 $\times 10^4$
		Voriconazole	-1.0 \pm 0.1	197.8
		Voriconazole N-oxide	-2.3 \pm 0.1	2.1 $\times 10^4$
Voriconazole N-oxide intermediate	-6.4 \pm 0.1	0.02		
		UK-215,364 [35]		

Results are presented as the mean \pm SD of three different replicates. *Kd* dissociation constant, *UDCA-G1* and *UDCA-G2* ursodeoxycholic acid glucuronide conjugate 1 and 2 [44], *UDPGlcA* UDP-glucuronic acid. Molecules with ΔG of < -0.1 and with an SD of ≤ 0.1 Kcal/mol were selected for further for MD simulations (methotrexate was not selected as it has an SD 0.5). SD is calculated from 8 docking poses or models (default option). The ligand binding pose was selected for further analyses is the pose with the lowest free binding energy (Kcal/mol). Bilirubin was selected for further molecular docking simulations as an endogenous negative control to compare our results with other putative ligands

Reference

1. Robin S, Hassine KB, Muthukumaran J, et al. A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation. *BMC Mol Cell Biol.* 2022;23:5. <https://doi.org/10.1186/s12860-021-00402-5>.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions



Table 5 Average values of hydrogen bonds, RMSD, RMSF, RoG, SASA, trace of the covariance matrix values and MM/PBSA binding free energy values of the different UGT2B10 with putative substrates

Complex	Average number of intra-molecular hydrogen bonds \pm SD	Average number of inter-molecular hydrogen bonds \pm SD	Average RMSD[nm \pm SD]	Average RoG[nm]	Average RMSF[nm \pm SD]	Average SASA[nm ² \pm SD]	Trace of the covariance matrix[nm ²]	MMPBSA binding free energy[kcal/mol]
UGT2B10 apo form	302.73 \pm 9.60	N/A	0.39 \pm 0.05	2.26 \pm 1.38*10 ⁻²	0.20 \pm 0.08	216.39 \pm 4.74	42.08	NA
UGT2B10-UDPGlcA	305.29 \pm 11.70	7.54 \pm 2.01	0.43 \pm 0.05	2.28 \pm 9.57*10 ⁻⁴	0.19 \pm 0.09	221.01 \pm 5.74	38.82	NC
UGT2B10-UDPGlcA-AMT	290.12 \pm 10.25	0.21 \pm 0.41	0.49 \pm 0.05	2.29 \pm 1.16*10 ⁻²	0.21 \pm 0.12	227.45 \pm 4.47	55.6	-160.85 \pm 10.99
UGT2B10-UDPGlcA-APAP	304.67 \pm 8.96	1.16 \pm 0.68	0.47 \pm 0.08	2.24 \pm 2.84*10 ⁻²	0.25 \pm 0.11	224.61 \pm 4.02	76.97	-174.24 \pm 13.38
UGT2B10-UDPGlcA-BIL	292.97 \pm 11.69	0.00 \pm 0.00	0.39 \pm 0.07	2.31 \pm 1.88*10 ⁻²	0.21 \pm 0.13	234.64 \pm 3.93	65.10	-104.00 \pm 11.06
UGT2B10-UDPGlcA-ITZ	310.11 \pm 10.43	0.24 \pm 0.44	0.51 \pm 0.05	2.33 \pm 1.29*10 ⁻²	0.23 \pm 0.14	244.84 \pm 6.86	60.70	-127.79 \pm 15.25
UGT2B10-UDPGlcA-LOR	300.25 \pm 8.69	0.65 \pm 0.79	0.42 \pm 0.06	2.28 \pm 1.14*10 ⁻²	0.20 \pm 0.10	230.58 \pm 3.67	48.81	-162.07 \pm 19.30
UGT2B10-UDPGlcA-MPA	303.7 \pm 9.09	2.48 \pm 1.33	0.47 \pm 0.05	2.33 \pm 1.21*10 ⁻²	0.22 \pm 0.16	230.48 \pm 6.97	60.23	-158.46 \pm 11.95
UGT2B10-UDPGlcA-VCZ	301.51 \pm 9.69	0.76 \pm 0.96	0.49 \pm 0.07	2.31 \pm 2.16*10 ⁻²	0.24 \pm 0.16	234.23 \pm 5.28	87.61	-59.56 \pm 17.13
UGT2B10-UDPGlcA-HVCZ	311.18 \pm 9.89	0.87 \pm 0.66	0.46 \pm 0.05	2.27 \pm 1.13*10 ⁻²	0.19 \pm 0.09	224.92 \pm 5.18	40.50	-85.43 \pm 14.23
UGT2B10-UDPGlcA-DHVCZ	308.33 \pm 9.97	1.21 \pm 0.83	0.43 \pm 0.04	2.29 \pm 1.13*10 ⁻²	0.20 \pm 0.10	227.99 \pm 4.71	43.27	-86.34 \pm 25.35
UGT2B10-UDPGlcA-4HVCZ	309.36 \pm 11.59	0.00 \pm 0.00	0.44 \pm 0.03	2.26 \pm 8.81*10 ⁻³	0.18 \pm 0.09	223.49 \pm 6.05	38.55	-95.43 \pm 18.47
UGT2B10-UDPGlcA-VCZ-N-O	303.01 \pm 10.28	1.38 \pm 0.78	0.43 \pm 0.05	2.30 \pm 1.28*10 ⁻²	0.22 \pm 0.11	233.91 \pm 5.20	58.16	-12.41 \pm 19.02
UGT2B10-UDPGlcA-VCZ-N-O-intermediate UK-215,364 [35]	305.54 \pm 12.28	0.72 \pm 0.52	0.38 \pm 0.03	2.3 \pm 1.19*10 ⁻²	0.18 \pm 0.1	227.28 \pm 4.55	37.75	-164.44 \pm 13.38

Results are indicated as mean \pm SD of the MD simulation's analysis results. 4HVCZ 4-hydroxy voriconazole, AMT amitriptyline, APAP acetaminophen, BIL bilirubin, DHVCZ Di-hydroxy voriconazole, HVCZ Hydroxy voriconazole, ITZ itraconazole, LOR lorazepam, MPA mycophenolic acid, NC Not calculated, VCZ-N-O voriconazole N-oxide, RMSD root mean square deviation, RMSF root mean square fluctuation, RoG radius of gyration, UDPGlcA UDP-glucuronic acid